Ivabradine was shown to attenuate chemokine-induced migration of CD4-positive lymphocytes in vivo [4], reduce vascular nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity in apolipoprotein E (ApoE)-deficient mice [5], improve the functioning of myocardial mitochondria in an infarcted pig heart [3], and reduce high-sensitivity C-reactive protein levels in patients with acute coronary syndrome [6]. This evidence concerns the gene APOE and acute coronary syndrome.